Small Company Champion & Lemming Investors Research and Newsletter Updates

Showing posts with label elric. Show all posts
Showing posts with label elric. Show all posts

Wednesday, 12 May 2021

Ava Risk Group - Material Uplift Pending



Ava Risk Group (ASX: AVA) has been disappointing this year and someway defies belief because the company has made astonishing progress on all fronts. Most companies have struggled due to covid-19; many have cut or not paid a dividend because the strategy is to preserve cash. AVA has bucked this trend by paying dividends, increasing net cash, increased margins, and debt-free; what’s not to like!

For now, the shares languish around the au$0.41c, which is 50% off their high but well ahead of my initial report at au$0.12c.

Thursday, 25 March 2021

AVA Risk Group - $1.8+ million Multi-Site Rail Contract Award



My Australian multi-bagger; Ava Risk Group Limited (ASX: AVA), is pleased to announce that its world-leading Aura Ai sensing solution has been selected to be deployed for a multi-site program to upgrade security at certain major rail facilities in South America:

  • Security upgrade program with a total award value of more than US$1.40 million (A$1.84 million).
  • Multiple Aura Ai-2 systems will be fully integrated with the customer’s existing video management software and CCTV system.
  • The first purchase order received exceeding US$0.47million (A$0.61 million).
  • Initial deployment at first sites in early Q4 FY2021 with the balance of sites expected for deployment before the end of Q4 FY2021.

Ava Group CEO Rob Broomfield said, “FFT Aura Ai-2 was the solution selected, to protect the rail sites, due to our exceptional event classification capability, extended sensing distance and cut resilience capability. A further key factor in the contract win was FFT’s previous success in protecting railway infrastructure and the company’s strong reputation across the broader transportation sector."

What is FFT Aura Ai-2?

AURA AI-2 PROVIDES TWO CHANNEL LONG RANGE HIGH SENSITIVITY INTRUSION DETECTION FFT Aura Ai-2 applies artificial intelligence to detect and locate skilled stealthy intruders climbing, cutting or lifting perimeter fences with high sensitivity. With two real-time simultaneous detection channels, Aura Ai-2 can be configured to provide cut resilience and redundancy. FFT Aura Ai-2 also provides high sensitivity detection in buried fibre applications such as covert buried or pipeline intrusion detection. FFT Aura Ai-2 is also perfect for monitoring fibre optic communications networks. The system can monitor tapping and tampering by connecting spare (dark) fibres inside each network cable to Aura Ai-2. Network cable disturbances, including removing protective layers, attempted tapping or cable movement, will be instantly detected and generate an alarm indicating the location. Aura Ai-2’s next-generation optoelectronics deliver industry-leading accuracy over an extended detection distance of 80 km (50 miles) on fences or 110km (70 miles) when buried. APPLICATIONS Intelligence Agencies Nuclear Facilities Data Networks Armed Forces Correctional Facilities Power Stations Oil and Gas Perimeters and Pipelines Airports Borders.

Today's news had little impact on the share price or created much attention on the forums; perhaps another A$1m PLUS is not exciting enough for the Australian investment community. Perhaps they are more expectant on another front. I know I am waiting for what I believe will be the game-changer for this company and the mining conveyor belt industry. Tests for the Aura IQ, I expect, will change the way big mining corporations mines manage conveyor belt maintenance. It is much safer, more accurate and more efficient than conventional monitoring methods and could save mining companies millions of dollars. 

The shares closed flat at A$0.51c, which is a multi-bag from my A$0.12c. I expect it to more than double again. I am keeping a tight grip on my shares because this is a fantastic little Australian company that will continue to grow. It has performed brilliantly over the past year; It has increased margins across the board, increased sales and generated record invoices. This company is only going to get better.

Monday, 22 March 2021

Spectra Systems - Phenomenal FY 2020


Spectra Systems Corp (SPSY) shares got a boost in early trading today (Monday) on the back of the positive report of a rise in revenue and profit for 2020 as demand for banknote materials and equipment increased. Not bad, given most companies have nothing but negative reports for 2020.

The Rhode Island-based company generated revenue of $14.7 million, up 11% from $13.2 million the prior year. Pretax profit increased by 20% to $5.4 million from $4.5 million. The firm declared an annual dividend of $0.095 per share and said share buybacks will continue.

Shares were up 4.5% at 170p bid at the close today; Spectra remains 5p lower than the Zulu Growth report on 7th February 2021.

Thursday, 4 March 2021

Spectra Systems - Sees 3.5x Increased Demand for Banknote Authentication Orders


''Just when you thought it was safe to get back into the water''

It appears recently that another Company featured within these pages, OptiBiotix appears to have abandoned the use of Proactive Investors to elaborate on its news flow.

Spectra Systems Corp

Spectra Systems sees 3.5x increased demand for banknote authentication orders from central banks

Hurrah some people say!

However, within days along comes the elusive CEO DR. Nabil Lawandy of secretive Company Spectra Systems with a Proactive interview, which as far as I am aware is a first from him or the Company. In my 6 or so years of being invested, I believe this is the first time I have ever witnessed him speak about the Company.

Is it worth watching and noting? Err. Actually Yes. The few simple questions are answered in detail by the CEO explaining the reason for its covert nature and that the long-predicted death of Banknotes in the media and Press is a figment of their imagination. If my understanding is correct, it also implies to me that Revenue wise 2023 appears transformational for the Company when the bulk of the $50m contracts from a major central bank kicks in. It also sheds a little more light on the Company and staff set up etc.

Of course, for us as investors, the key question is when will the market start to price it in?

Enjoy, but shhhh, don’t tell anyone.

Spectra Systems sees 3.5x increased demand for banknote authentication orders from central banks (

In the meantime, we wait patiently for 2020 Results which should be out later this month, hopefully with forecasts for 2022 and increased earnings forecasts for 2021. There are no guarantees of course.

Tuesday, 9 February 2021

Open Orphan - Opportunities Key Events Rocket Boosters


The most recent webinar by Open Orphan Plc (ORPH) was again very encouraging on several fronts. It is not unusual for a webinar - Investor presentation not to be optimistic. What is out of the ordinary, from my experience, is the level of opportunities, primers for significant appreciation for even more share price gains; yes, even after the 400% plus increases in 2020, and the bull gains in 2021. Had it not been for Invesco selling down, Open Orphan would likely be north of 40p now.

So what of these opportunities? 

The highlights for me are as follows:

  • The company could be split from its core business resulting in 3 in-species dividends; is 1 for 1 Cathal explained.
  • PrepBiopharm, Influenza Immune Modulator & disease in motion (DIM)
  • He explained the first of these (Imutex) could be as early as 4-6 weeks. He explained Covid-19 had hindered progress but stressed this is very close now.
  • Two further spin-outs, again, one Open Orphan share, one newco share
  • Chinese very keen on challenge studies 
  • Potential huge Covid CHIM licensing deals/studies with the Chinese State
  • Emphasis profitable no more losses 
  • The expectation is to reach a market value of  £1bn as being realistically achievable.
  • FY results after easter - they will not disappoint.
  • Looking for investors stake build 
  • Six challenge models
  • Company is the world leader in testing vaccines via Controlled Human Infection Models (CHIMs)
  • New ''Disease in Motion'' (DIM) platform with potential current market cap valuation of £200m
  • DIM could be spun-out
  • New Whitechapel Quarantine Clinic opened February 2021 with an expanded 19-bed capacity.
On of the question that I could understand (sound issues - mad echo), not, it wasn't a ramping echo chamber. Cathal explained that competitors out there could challenge the company's status as the world leader in disease challenge studies, but expressed scepticism a real challenge would be successful due to the global situation the company has, plus high entry barriers and the time required to gain credibility.

There was a lot of excitement around the DIM - this was pleasing to me because it is exactly the area of the business I emphasised has huge financial implications for the future; its pretty much free cash. On top of the enormous revenues coming in from the vaccine studies, which will be a cash cow for the foreseeable years; it is clear the UK government contract worth £46m for the CHIM's is just the start, not the end, even so, this is a small part of the business. 

Disease In Motion

Intelligent Wearable Technologies and Clinical Applications in Low- and Middle-income Countries (LMIC)

''The webinar will discuss the growing medical applications of wearable technologies for healthcare and potential roles in guiding clinical and public health decision-making. Ongoing work between Imperial College Centre for BioInspired Technology and Oxford University Clinical Research Unit, Vietnam in development and clinical evaluation of these technologies for infectious diseases management will be introduced. This work forms part of a multi-national collaboration funded by the Wellcome Trust Flagships Award.''

Global Smart Devices Market - Huge and Growing Fast

The global wearable medical device market size was valued at USD 13.0bn in 2019 and is expected to witness a CAGR of 27.9% over the forecast period. The growth of industries, such as home healthcare and remote patient monitoring devices, is anticipated to positively influence wearable devices' demand. Besides, increasing consumer focus on fitness and leading a healthy lifestyle positively fuel the product demand.
More from the report here.

The Global Smart Healthcare Market size stood at US$ 141bn in 2019 and is expected to grow at 14.5% through 2030. Smart Healthcare is technology integrated diagnostic tool used for treating patients and improving the quality of life using e-health, m-health and ambient assisted living services. Rising government initiatives for the digitization of healthcare infrastructure are driving the growth of the smart healthcare market.
More from the report here.

The number of connected wearable devices worldwide has more than doubled in the space of three years, increasing from 325m in 2016 to 722min 2019. The number of devices is forecast to reach more than one billion by 2022.

Two important factors to the growth within the wearable devices market are primarily being powered by sales of smartwatches – shipments of smartwatches worldwide are forecast to surpass 100m in 2020. Apple, who unveiled their first smartwatch in 2015, currently dominate the smartwatch market and have held a share of around 45% since 2018. Another reason for the growth of the wearables market is the rise in popularity of wearable devices. Also referred to as earwear or ear-worn devices, this category is expected to soar over the next few years with shipments of devices forecast to increase by 45% to 105m units by 2023.
Any search you chose to do for smartwatches, or health monitoring devices will vary from the cheap and nasty, to the premium expensive kind. What is important as far as we are concerned, and Open Orphan, of course, is that the company has a very lucrative database of infectious diseases. Some of the world's largest companies are seeking to supplant in their wearable smart devices. While these devices may have been around for a while, and in some cases become a short-term fad for the post-Christmas fitness bunny, I think, as do Apple and Amazon, probably others, a new more important market has just opened up, one that has the potential to save lives as well as monitor health and wellbeing on an all-new level previously only health care professionals had access too. 

Open Orphan is one of my multi-baggers for 2021

Friday, 5 February 2021

Ramsdens Holdings - A Post Covid-19 Dividend Paying Recovery

Today's feature was first submitted to members on 29th January. To learn how to obtain these reports earlier than general release, please click on the link.


Ramsdens Holdings Plc (RFX) is a financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking & logbook loans, buying and selling precious metals and retailing of second hand and new jewellery through its network of 127 stores throughout the UK, including 3 franchised stores, and has a small and growing online presence. 

In the last financial year, the Group served over 700,000 customers across its different services. Ramsdens is a trading name of Ramsdens Financial Limited and is authorised and regulated by the Financial Conduct Authority for consumer credit activities. 

Powder Monkey Brewing Co has nothing to do with Ramsdens, they just brew superb ales at great prices. The company was set up by a good friend of mine. You may know as Mike McGeever and his good friend, ex England hooker, Steve Thomson.

Robust Trading despite Covid-19 

Like all high street businesses, trading in 2020 and early 2021 has been exceptionally tough. The company appears to have taken a proactive measure to preserve cash even in the face of   Revenue growth of 27% (£76.9m) and gross profit growth of 22% (£47.1m), the company decided to cancel the final dividend.

It is likely most, if not everyone reading this will not have a need to use the services of a pawn brokerage, unless you have an eye for a bargain. I dare say you may have walked past them on the high street and not paid any mind. So, here's a brief overview of the business.

The primary service is loans for people with poor credit or in need of a short term small loan banks will not entertain. Typically you need to own something of value. If you take it to a pawn shop, they will be able to give you cash immediately. You then pay interest every month, if not daily, until you want to repurchase the item for the amount you borrowed against it. The item must have a salable value equal to or larger than the loan that is being issued.

Due to the high-interest rate, most loans are short term vary subject to credit check and creditworthiness. The company reported a 60% increase in the loan book.

If interest is not paid, the pawnshop keeps selling the item that was put up for collateral. If the customer pays back the loan (with interest) on time, the item is returned to the customer. A loan of this type is a non-recourse loan, which means that the pawnshop may only collect the item being pledged as collateral in the event of default by the borrower.

I will not drag this report out, it does not warrant a lengthy article because the business is not that complex, plus the key data is easily visualised in the many graphs I have uploaded for you to take your cue. They do say a picture says a thousand words. Those familiar with my predicament with dyslexia will know this has saved me many hours, probably a day proofing through various filters.

Pawnbrokers are not cheap for the ordinary person on a low income, but they are in some cases, a much-needed safety net for people in need of short term cash-bridge to see them through to the next payday. This is why the government gave these type of services critical status after the first lockdown.

Equally, they are an easy source of ready cash for someone purging their unwanted goods that have some cash value. One man's crap is another man's gold...something like that! It is easy to forget that pawnbrokers are jewellers in their own right. When I browsed through the site,, I quickly established a high-quality jewellery demand, like high-end watches, bracelets and rings, easily shipped small packages. The business's online side is small, but this will grow as regular customers become familiar with it. This side of the business is not likely to become the core because there is an overwhelming need for customer-facing interaction with physical goods, and this is, of course, a quicker route to cash, it how the haggling is done.

Do not make the mistake of assuming Ramsdens sell low-value cheap tat; the ring above has a price tag of £14,499 or £182.05 per month.

Patek Philippe
Pre Owned Patek Philippe Annual Calendar Ref 5396G 014

Rolex Daytona Pre Owned Watch Ref 116505
Pre Owned Patek Philippe Annual Calendar Ref 5396G 014

The loan book side is something I am right pleased I have never needed to use, even though they are typically for a few hundred pounds and not tens of thousands; an APR of 154% or 9% per month can cripple some families on the breadline. It is easy to see how some low-income customers may find themselves rolling over month after month. They can be thankful the APR is not 4 digit APR we often see advertised and the added bonus, their services can be all the difference from keeping the needy out of harm's way that is the loan sharks.

Yeah, I get it, this is not sexy, certainly nowhere near as exciting as chasing the next rainbow stock. This is not what this site is about, it is intended to seek, or hunt-down solid growth companies and if we can catch them ahead of a recovery uptick after they have taken a kicking, then so be it. With Ramsdens, we have a post-Covid-19 recovery play, plus a nice dividend (subject to the company cancelling it) this comes in at 3.1%.

Like many publicly-facing retail outlets, Ramsdens share price has been hit hard from the outset of Covid-19 pandemic. The shares took a swan-dive down to a year low of 68p; they have since recovered if flatlining for most of the year in a tight range around 140p constitutes a recovery while the shares remain someway off the pre-Covid-19 high of 257p. 

As you can see from the chart that begins at the March selloff, there is a prolonged consolidation period with a tilt to the slow downside. I view this as an opportunity to scale-in until such a time, the company offers further guidance. This is subject to your belief, or not as the case may be, of how quickly we are released from the hell of lockdown. 

Ramsdens has not been as hard hit as some highstreet outlets, in the main because most of the stores have remained open for business with safeguards. Even as the country was entering its second national lockdown, Ramsdens announced the UK Government has categorised the company as essential, which of course means the company can remain open for business. As a result, the Group said it expects to keep open more than 90% of its UK store estate during the current national lockdowns imposed in EnglandScotland and Wales, albeit with shortened trading hours. This is of course great news for the company and likely a much-needed lifeline in certain communities in need of cash due to prolonged furlough, or worse, a vital financial bridge for some families that have lost their jobs and find themselves in the bureaucratic minefield attempting to claim state aid. Even so, not everyone can survive on 76% of their salaries; so hocking off those golf clubs, old mobiles, music equipment or jewellery is viewed as an essential service and an important lifeline for cash-strapped individuals and families. OK, this is a really simplistic view and ignores the rest of the business. However, it merely serves a purpose that is to highlight the possible recovery play here the wider market has not picked up on. 

The flatlining of the share price for a prolonged period suggests the market has already factored in the Covid-19 turmoil and is waiting for guidance from the company, perhaps hope that earnings have continued to grow, even if they are not at the same rate pre-Covid-19.

What follows is part of a new feature you will become familiar with. There are three reasons for this. 1. It saves me a lot of time explaining key data 2. If you are anything like me, a visual presentation of key statistics is easier for me to quickly read and understand 3. This feature should be of great benefit to you and in some way, explains my logic for choosing the company featured. 

So, lots and lots of data is expensive via a premium offering I can share with you.

As we can see, one of the key metrics, EPS grew by an impressive 23% last year. The strong recent performance means it was also able to grow EPS by 168% over the last three years.

As we can see from the sector comparison chart, Ramsdens outperformed its peers. Moreover, until Covid-19 struck, there were 5 consecutive years of growth along with a modest IBIT up-trend.

I guess the big question is how long we continue with the national lockdown, and will it be lifted in time for the holiday season; this being the main concern is if holiday bookings don't take off as we hope after COVID-19 if lockdown is extended to say the Autumn?  and the currency exchange takes a hit. The CEO seems well respected.

The company does have a strong online presence. I was browsing the watch section, and to my surprise, there are many high-end watches with the option for higher purchase with a typical APR of 9%, subject to credit checks I imagine. 

All things being equal before Covid-19, at some point I think they will return to at least 10% growth p.a.  This is more pedestrian than some of the companies on the mother site, where I write about fledgelings, startups, and pre-commercial companies with big dreams, some of which have proven to be very exciting as well as lucrative. Hopefully, notwithstanding national disaster's, we should not suffer the wild pitfalls that have befell Ramsdens in the first part of 2020. 

Quick Glance at Key Data

Ramsdens Financial Results for the 18 months ended 30 September 2020

Financial highlights

  • Strong growth in the 12-month period to March 2020 and profitable performance in the final 6-month period despite the impact of Covid-19;
  • Revenue of £76.9m for the Period; Revenue growth of 27% for the comparable 12-month period ended 31 March 2020;
  •  Gross Profit of £47.1m for the Period; Gross profit growth of 22% for the comparable 12-month period ended 31 March 2020;
  • Profit Before Tax of £9.2m for the Period; Profit Before Tax growth of 30% for the comparable 12-month period ended 31 March 2020;
  • Robust cash position, with net cash of £15.9m as at 30 September 2020 and an undrawn £10m revolving credit facility;

Against the backdrop of considerable ongoing uncertainty, challenging trading conditions and continuing to receive government support to protect jobs, the Board believes it is both prudent and in the long-term interest of shareholders to retain its cash resources to trade through this period. This will position the Group to maximise the opportunity when the 'new normal' returns. As a result, the Board is not recommending a final dividend for the Period.

Operational highlights

  • One net store opening after merging eight stores with nearby Ramsdens stores resulting in 153 owned stores at the Period end; four stores relocated in the Period;
  • Continued progress in jewellery retail with £1.9m of e-commerce sales in the Period, representing 9% of all jewellery items sold; 40% of online jewellery sales now made to customers living outside the natural catchment area of the store network;
  • Before the impact of COVID-19, during the year to March 2020, a record of approximately 784,000 customers used the Group's foreign currency service;
  • 6 pawnbroking loan books acquired during the Period; the loan book is considered of high quality with a low loan to value ratio of approximately 60% and an average loan value of £248 as at 30 September 2020;

Peter Kenyon, Chief Executive, commented:

"The 18-month period covered by this statement can be broken down into two distinct sections. Firstly, Ramsdens delivered its strongest ever 12-month performance before the impact of COVID-19 when the business achieved further growth and made strategic progress across each of its income streams. The subsequent impact of COVID-19 and the enforced closures of stores and international travel restrictions demonstrated our diversified business's resilience models resilience. Despite the significant headwinds experienced since March due to the pandemic, we have continued to trade profitably and maintain a strong cash position.

The credit for the Group's performance and continued progress despite these truly unprecedented conditions must go to our committed team and loyal customers. I would like to thank everyone in the Ramsdens community for their fantastic support during this period.

As we move into 2021, a lot of uncertainties remain. However, there are promising signs in the form of a vaccine and - whatever the outcome is - we will have greater clarity regarding what Brexit means for consumers and businesses. Whilst the pandemic has had an unimaginable impact on communities and companies across the UK, we remain very confident that underpinned by our great value customer proposition, strong balance sheet and diversified model, we remain well-positioned to continue our growth trajectory as normality resumes."

This report was first sent to members via email a week before publication. 



Updates, new content and interviews will be sent to Premium & donor's first.

I realise it is human nature to push against the established norm - 2 years of free research. 
The site data suggest my research is valued by many, but few actually contributed in those 2 years. 
Each research report is carefully researched over many weeks. The content has proven very popular; indeed many readers have invested in the companies featured, many of which have proven to be a great success, including multi-baggers like; AVA Risk Management, OptiBiotix Health, PowerHouse Energy Group, SkinBioTherapeutics, Seeing Machines.

Those of you who have seen the value in work do thank you for your donation, whatever the amount is gratefully received. If you haven't already, please show your appreciation for the many hours of dedicated research, plus company updates and BOD interviews as well as the conduit between investors and BOD. 

Rainbow Chase - (£25 ANNUALLY UNTIL OPT-OUT)- The feature is designed to discover precommercial companies with exciting growth potential. These carry significant risk for failure, but also due to their nature have significant multi-bagger potential. PLEASE PAY HERE!
All existing features are covered by this level.

Zulu Growth - (£35 ANNUALLY UNTIL OPT-OUT) The focus will be on mid-cap companies, but not exclusively. These companies are less risky than Rainbow Chasing because they are carefully selected using specific filters designed to highlight companies that have demonstrated several specific growth indicators over a specific period. By their very nature, these companies are long term features. Zulu Growth offers visual aids for key data designed to offer an overview supporting the direction of travel a company is inPLEASE PAY HERE!

MULTI-BAG IT - (Rainbow Chaser + Zulu Growth for £50 ANNUAL UNTIL OPT-OUT) PLEASE PAY HERE!

Recently donated?
Don't worry. I very much appreciate those of you that have supported me. If you donated at the beginning of the year, you qualify as a Premium member (subject to Rainbow Chasing fee).

The donation link below is an addon. The monies collected from this will be donated to a chosen charity. This years charity will be the Salvation Army Failsworth Corp (my home church which has been hit badly due to Covid-19)

Monday, 1 February 2021

Open Orphan - Contact Renewal with Carna - Adds Significant Revenues in 2021


There is not much to be said about today's announcement from Open Orphan (ORPH) announcement to extend its contracts with Carna Bioscience, Inc., other than to say this was not the announcement I was expecting this morning or anyone else in the investment community and offers assurance post-Brexit normal service has resumed with European partners and indeed the wider business community. I have asked the company's PR for comment, as yet, nothing. Anna is usually quite good or has been in the past, so I have some hope. Even so, I suspect we will learn more during the investor presentations on Wednesday.

I guess we can add the following Tweet to the above Tweet which offers further encouragement as well as raises more questions for Cathal on Wednesday. 

The Tweet appears to be a Flucamp banner on the side of Whitechapel Hotel with 27 bedrooms and immediately opposite the existing 24-bed quarantine facility in East London. Could this be the 3rd facility!? Asks @Eskers1

So, back to the announcement the rapidly growing speciality pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc. ("Carna"), extending its integrated drug development consultancy services with Venn Life Sciences ("Venn"), part of Open Orphan plc.

Carna Biosciences is a clinical-stage biopharmaceutical company founded in April 2003 in Kobe, Japan to discover and develop innovative therapies to treat serious unmet medical needs, focusing on small molecule drugs, mainly targeting kinases. We also offer a broad range of high-quality products and innovative drug discovery services to scientists worldwide to efficiently identify new kinase inhibitors. Open Orphan and Carna Bio will be focusing on small molecule drugs. The renewal of this contract is expected to deliver significant revenue for Venn over the next twelve months. 

The VENN teams in the Breda office in Holland will provide Chemistry, Manufacturing & Control (CMC), Non-Clinical, Clinical and Regulatory consultancy services to this client for two of the client's leading development programmes. This successful collaboration has been extended until the end of December 2021.

Cathal Friel, Executive Chairman of Open Orphan, said: "The extension of this contract further demonstrates our ability to collaborate successfully with our clients and provide a service that results in repeat business. Venn and Carna have built up a good working relationship over a period of several years where both parties closely collaborated on drug development planning and its execution through consultancy services contracts. We look forward to delivering this contract for Carna in the year ahead."

Masaaki Sawa, Ph.D., Chief Scientific Officer and Head of Research and Development at Carna Biosciences, said: "The partnership with Venn Life Sciences complements our clinical development team and underlines our commitment to become a clinical-stage company. By continuing the collaboration with the Venn team, we will accelerate our drug development."